Breast Cancer

Lynparza Approved for Germline BRCA-Mutated Metastatic Breast Cancer

By January 12, 2018

It is the first time any drug has been approved to treat certain patients with metastatic breast cancer who have a "BRCA" gene mutation.

Survival Rates Assessed for Young-Onset Breast Cancer With <i>BRCA</i> Mutation

January 12, 2018

The researchers found that 12% of patients had a pathogenic BRCA mutation. Overall, 96% of the 678 deaths were due to breast cancer after a median follow-up of 8.2 years.

Breast Implants Increase Rare Type of Lymphoma

January 05, 2018

"Our results emphasize the need for increased awareness among the public, medical professionals, and regulatory bodies; promotion of alternative cosmetic procedures; and alertness to signs and symptoms of breast-ALCL in women with implants," the authors write.

Stereotactic Radiotherapy System FDA-Cleared to Treat Breast Cancer

By December 26, 2017

The GammaPod system is intended for use in the noninvasive stereotactic delivery of a radiation dose to a portion of the breast in conjunction with breast conserving treatment.

Perjeta Gains New Indication for Early Breast Cancer

By December 21, 2017

Approval was based on data from APHINITY, a multicenter, randomized, double-blind, placebo-controlled trial in 4804 patients with HER2-positive early breast cancer who had their primary tumor excised prior to randomization.

First Dose-Escalation Study Examines Ulixertinib for Advanced Tumors

December 18, 2017

The researchers found that ulixertinib exposure was dose-proportional to the RP2D and almost completely inhibited ERK activity in whole blood.

Accuracy of Artificial Intelligence Assessed in CA Diagnosis

December 12, 2017

The researchers found that the AUC of the DLS for referable diabetic retinopathy was 0.936, and sensitivity and specificity were 90.5 and 91.6%, respectively

Acupuncture May Relieve Aromatase Inhibitor-Linked Joint Pain

December 08, 2017

The researchers found that the 6-week mean BPI worst pain scores were 0.92 points lower in the true acupuncture versus sham acupuncture arm, and 0.96 points lower in the true acupuncture versus waitlist control arm.

Kisqali Shows Promise in Premenopausal Breast CA Population

By December 08, 2017

Results found a median PFS of 23.8 months (95% CI: 19.2 months-not reached) for the Kisqali group compared to 13.0 months (95% CI: 11.0-16.4 months) for tamoxifen or an aromatase inhibitor plus goserelin (HR=0.553; 95% CI: 0.441-0.694; P<0.0001).

'No Rationale' for Extended Anastrozole Tx in HR&#43; Early Breast CA, Study Finds

December 08, 2017

"There is simply no rationale to keep most patients on extended aromatase inhibitor for longer than two years," said lead author Michael Gnant in a statement.

Hormonal Contraceptives and Breast Cancer: What's the Link?

December 07, 2017

Findings from nationwide study in Denmark show small absolute increase in breast cancer risk

Ribociclib Addition Assessed for PFS in HR&#43; HER2&#8722; Advanced Breast CA

December 07, 2017

Researchers conducted a randomized phase III trial assessing ribociclib + tamoxifen/non-steroidal aromatase inhibitor and goserelin in pre- and peri-menopausal women.

FDA Approves Second Biosimilar for the Treatment of Cancer

By December 01, 2017

Ogivri is the first biosimilar approved in the U.S. for the treatment of breast cancer or stomach cancer and the second biosimilar approved in the U.S. for the treatment of cancer.

Faslodex Approved as Combo Tx for Advanced Breast Cancer

By November 15, 2017

The FDA approval is based on data from the Phase 3 MONARCH 2 trial, which met the study's primary endpoint of PFS.

Breast Cancer Recurrences Steady After Therapy Cessation

November 10, 2017

The risk of distant recurrence was 13, 20, and 34%, respectively, among patients with stage T1 disease with no nodal involvement (T1N0), with one to three nodes involved (T1N1-3), and with 4 to 9 nodes involved (T1N4-9).

Adipocytes May Clear Daunorubicin, Contribute to Poorer Survival Outcomes

November 09, 2017

The researchers found that adipocytes absorbed and metabolized daunorubicin to daunorubicinol, which reduced its anti-leukemia effect. Daunorubicin conversion to daunorubicinol was confirmed in vivo in murine studies.

Experts Pick the Top 10 Medical Innovations for 2018

By November 03, 2017

The panel - made up of nearly 100 physicians and scientists - debated and whittled down over 150 nominations to decide upon the final 10.

Xenografts Show Therapeutic Potential for PARP Inhibitors Beyond <i>BRCA1/2</i>

November 02, 2017

Researchers generated 26 breast cancer patient-derived xenografts (PDXs) from surgical samples of primary or locally recurrent tumors from 25 patients.

Elastography and Color Doppler Evaluated in Breast Screening

October 30, 2017

The addition of elastography and color Doppler US to B-mode US increased the area under the receiver operating characteristic curve from 0.87 to 0.96 (P<0.001) and specificity from 27 to 76.4% (P<0.001) without loss in sensitivity.

FDA Approves Verzenio for Advanced or Metastatic Breast Cancer

By September 28, 2017

Verzenio is an inhibitor of cyclin-dependent kinases 4 and 6 (CDK4 and CDK6).

Potential Prognostic Biomarker ID'd for Triple-Negative Breast CA

September 26, 2017

African-American patients harbored significantly more tumor-infiltrating lymphocytes than European Americans among early-stage (I to II), but not late-stage (III to IV), patients.

Weight May Play Role in Selecting Treatment Strategy for Breast CA Patients

September 20, 2017

BMI was positively correlated with ER+/PR+ and ER−/PR− subtype risks, with a significant association only seen for ER+/PR+ subtypes.

Multivitamins Tied to Reduced Risk of Chemo-Induced Neuropathy

September 13, 2017

The researchers found that there was an association for multivitamin use before diagnosis with reduced symptoms of CIPN (CTCAE-adjusted odds ratio, 0.6 [95% confidence interval, 0.42 to 0.87]; FACT/GOG-Ntx-adjusted OR, 0.78 [95% confidence interval, 0.61 to 1]).

Handheld Pen Device Rapidly Detects Cancerous Tissue

By September 08, 2017

Researchers at the University of Texas, who developed the MasSpec Pen device, tested its capability on 20 thin tissue sections (including breast tissues, thyroid tissues, papillary thyroid carcinoma, and follicular thyroid adenoma tissues) and 253 human patient tissue samples (including lung, ovary, thyroid and breast samples) some normal and some cancerous.

Mammography Device with Patient-Assisted Compression Gets FDA Approval

By September 05, 2017

Using a handheld wireless remote control, the patient can adjust the compression force after breast positioning by a technologist.

Non-Hormone Options Recommended for Depletion After Breast CA

August 30, 2017

The researchers recommend that women should not generally be treated with menopausal hormone therapy or tibolone following breast cancer, but should optimize lifestyle.

Faslodex Monotherapy Now Approved for HR+, HER2- Advanced Breast Cancer

By August 28, 2017

The approval was supported by data from the Phase 3 FALCON trial (n=462) that enrolled postmenopausal women with HR+ metastatic or locally advanced breast cancer.

Light at Night and Breast Cancer: Is There a Link?

August 21, 2017

The team found that breast cancer levels in premenopausal women who currently smoked or had smoked in the past grew by 14% if they were in the 20% deemed to have had the most exposure to outdoor light at night.

Cancer Survival for Alternative vs. Usual Treatment Examined

August 18, 2017

Alternative medicine was independently associated with greater risk of death compared with conventional cancer treatment overall (hazard ratio [HR], 2.50), as well as in subgroups with breast (HR, 5.68), lung (HR, 2.17), and colorectal cancer (HR, 4.57).

Cancer, CV Risks Examined for Vaginal Estrogen Tx in Postmenopausal Women

By August 16, 2017

The data showed women with an intact uterus did not have a significantly different risk of stroke, invasive breast cancer, colorectal cancer, endometrial cancer, and pulmonary embolism/deep vein thrombosis (PE/DVT) between those who used vaginal estrogen and those who did not.